American Oriental Bioengineering, Inc. (AOBI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2012 | 67.64 Million USD | -41.91% |
| 2011 | 116.44 Million USD | -5.51% |
| 2010 | 123.23 Million USD | -4.9% |
| 2009 | 129.58 Million USD | 2.41% |
| 2008 | 126.53 Million USD | 1130.19% |
| 2007 | 10.28 Million USD | -6.52% |
| 2006 | 11 Million USD | 196.0% |
| 2005 | 3.71 Million USD | -27.22% |
| 2004 | 5.1 Million USD | 245.58% |
| 2003 | 1.47 Million USD | 2.23% |
| 2002 | 1.44 Million USD | 0.0% |
| 2001 | - USD | -100.0% |
| 2000 | 245.83 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2013 Q1 | 62.67 Million USD | -7.34% |
| 2013 Q3 | 92.76 Million USD | 43.42% |
| 2013 Q2 | 64.68 Million USD | 3.21% |
| 2012 Q1 | 119.56 Million USD | 2.68% |
| 2012 FY | 67.64 Million USD | -41.91% |
| 2012 Q4 | 67.64 Million USD | 0.64% |
| 2012 Q3 | 67.21 Million USD | -45.58% |
| 2012 Q2 | 123.51 Million USD | 3.31% |
| 2011 FY | 116.44 Million USD | -5.51% |
| 2011 Q4 | 116.44 Million USD | -5.81% |
| 2011 Q3 | 123.61 Million USD | -1.25% |
| 2011 Q2 | 125.18 Million USD | 1.28% |
| 2011 Q1 | 123.6 Million USD | 0.3% |
| 2010 Q2 | 125.83 Million USD | -2.81% |
| 2010 Q1 | 129.47 Million USD | -0.08% |
| 2010 Q3 | 123.08 Million USD | -2.18% |
| 2010 FY | 123.23 Million USD | -4.9% |
| 2010 Q4 | 123.23 Million USD | 0.12% |
| 2009 FY | 129.58 Million USD | 2.41% |
| 2009 Q1 | 126.56 Million USD | 0.02% |
| 2009 Q2 | 125.56 Million USD | -0.79% |
| 2009 Q3 | 129.55 Million USD | 3.18% |
| 2009 Q4 | 129.58 Million USD | 0.02% |
| 2008 Q1 | 10.57 Million USD | 2.85% |
| 2008 FY | 126.53 Million USD | 1130.19% |
| 2008 Q4 | 126.53 Million USD | 0.59% |
| 2008 Q3 | 125.79 Million USD | 1067.13% |
| 2008 Q2 | 10.77 Million USD | 1.88% |
| 2007 Q1 | 10.44 Million USD | -5.07% |
| 2007 Q2 | 11.23 Million USD | 7.57% |
| 2007 Q3 | 10.04 Million USD | -10.62% |
| 2007 Q4 | 10.28 Million USD | 2.43% |
| 2007 FY | 10.28 Million USD | -6.52% |
| 2006 Q3 | 10.95 Million USD | 10.96% |
| 2006 FY | 11 Million USD | 196.0% |
| 2006 Q1 | 3.74 Million USD | 0.66% |
| 2006 Q2 | 9.87 Million USD | 163.92% |
| 2006 Q4 | 11 Million USD | 0.41% |
| 2005 Q4 | 3.71 Million USD | -0.72% |
| 2005 Q3 | 3.74 Million USD | -26.58% |
| 2005 Q2 | 5.1 Million USD | -0.07% |
| 2005 Q1 | 5.1 Million USD | -0.08% |
| 2005 FY | 3.71 Million USD | -27.22% |
| 2004 Q3 | 1.56 Million USD | 6.3% |
| 2004 Q4 | 5.1 Million USD | 225.97% |
| 2004 FY | 5.1 Million USD | 245.58% |
| 2004 Q1 | 1.47 Million USD | -0.15% |
| 2004 Q2 | 1.47 Million USD | -0.12% |
| 2003 Q2 | 1.44 Million USD | 0.0% |
| 2003 Q1 | 1.44 Million USD | 0.0% |
| 2003 FY | 1.47 Million USD | 2.23% |
| 2003 Q4 | 1.47 Million USD | 2.23% |
| 2003 Q3 | 1.44 Million USD | 0.0% |
| 2002 Q4 | 1.44 Million USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | 1.44 Million USD | 0.0% |
| 2002 Q3 | 1.44 Million USD | 0.0% |
| 2002 FY | 1.44 Million USD | 0.0% |
| 2001 Q2 | - USD | -100.0% |
| 2001 Q3 | 333.33 Thousand USD | 0.0% |
| 2001 Q4 | - USD | -100.0% |
| 2001 FY | - USD | -100.0% |
| 2001 Q1 | 315.5 Thousand USD | 28.34% |
| 2000 Q2 | 444.8 Thousand USD | 137.23% |
| 2000 Q1 | 187.5 Thousand USD | 0.0% |
| 2000 Q4 | 245.83 Thousand USD | 0.0% |
| 2000 FY | 245.83 Thousand USD | 0.0% |
| 2000 Q3 | - USD | -100.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -64.17% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -1541.037% |
| SQZ Biotechnologies Company | 27.47 Million USD | -146.234% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -55.956% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -127.24% |
| Mesoblast Limited | 118.7 Million USD | 43.014% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -7033.282% |
| Genus plc | 233.1 Million USD | 70.981% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -2208.324% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -4934.508% |
| Marizyme, Inc. | 18.71 Million USD | -261.388% |
| ContraFect Corporation | 2.88 Million USD | -2247.895% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -8919.047% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -49825.712% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -4576.897% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -2808.175% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -1095.451% |
| MultiCell Technologies, Inc. | 202.58 USD | -33390584.668% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -17.662% |
| EV Biologics, Inc. | 1.49 Million USD | -4425.359% |
| Q BioMed Inc. | 4.1 Million USD | -1545.819% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -104.353% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -10635.648% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -5406.756% |
| Biomind Labs Inc. | 735.54 Thousand USD | -9096.327% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 60.568% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -420.45% |
| Skye Bioscience, Inc. | 4.61 Million USD | -1365.633% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -7516.889% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -47698.053% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -1052.134% |
| IMV Inc. | 28.88 Million USD | -134.189% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -262907.306% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -2895.192% |
| GB Sciences, Inc. | 1.75 Million USD | -3744.858% |
| Alpha Cognition Inc. | 1.22 Million USD | -5442.806% |
| HST Global, Inc. | 98.31 Thousand USD | -68699.366% |
| CSL Limited | 12.18 Billion USD | 99.445% |
| Halberd Corporation | 150 Thousand USD | -44995.233% |
| Enzolytics Inc. | 996.33 Thousand USD | -6689.147% |
| Resverlogix Corp. | 6.49 Million USD | -942.102% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -14066.042% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -26365.167% |
| argenx SE | 20 Million USD | -238.214% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -48.47% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -2397.241% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -661443.756% |
| Genscript Biotech Corporation | 417.73 Million USD | 83.807% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -33617.574% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -2721.127% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -29400.874% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -2135.247% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -18704.829% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -232.757% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -45403.551% |
| BioStem Technologies, Inc. | 4.71 Million USD | -1335.722% |
| ONE Bio Corp. | 19.71 Million USD | -243.103% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -26937.456% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -27096.385% |
| Agentix Corp. | 50 Thousand USD | -135185.698% |
| LadRx Corporation | 33.6 Thousand USD | -201182.06% |
| Cell Source, Inc. | 9.25 Million USD | -630.944% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -8845.053% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -8845.053% |
| NovAccess Global Inc. | 2.19 Million USD | -2974.843% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -856.379% |
| Itoco Inc. | 228.37 Thousand USD | -29518.941% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -31962.021% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -1257.472% |
| Kadimastem Ltd | 891.22 Thousand USD | -7489.865% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -16732.902% |
| CytoDyn Inc. | 30.07 Million USD | -124.906% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -13867.599% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -19125.075% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -765.002% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -55118.652% |
| Rebus Holdings, Inc. | 310 Thousand USD | -21720.274% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -1328.486% |
| International Stem Cell Corporation | 4.17 Million USD | -1519.025% |
| Bioxytran, Inc. | 1.92 Million USD | -3413.914% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -108279.423% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -3001.603% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -713.406% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -687.919% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -4248.683% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -25139.869% |
| Neutra Corp. | 54.15 Thousand USD | -124803.702% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -3596.331% |
| PureTech Health plc | 25.51 Million USD | -165.141% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -5425.356% |
| IXICO plc | 472.02 Thousand USD | -14230.414% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -336.377% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -8.641% |
| CSL Limited | 12.18 Billion USD | 99.445% |
| Cellectis S.A. | 92.77 Million USD | 27.091% |